What is the appropriate dosing regimen of mirtazapine (Remeron) for appetite stimulation in a 72-year-old patient?

Mirtazapine Dosing for Appetite Stimulation in a 72-Year-Old Patient

Start mirtazapine at 15 mg once daily at bedtime, then increase to 30 mg daily after 1–2 weeks if tolerated; this is the evidence-based regimen for appetite stimulation and weight gain in older adults. 1

FDA-Approved Dosing Framework

• Initial dose: 15 mg once daily, preferably in the evening before sleep. 1
• Titration: Increase to 30 mg daily after 1–2 weeks if the patient tolerates the initial dose and requires greater appetite stimulation. 1
• Maximum dose: 45 mg daily, though doses above 30 mg have not been systematically studied for appetite stimulation specifically. 1
• Timing of dose adjustments: Allow at least 1–2 weeks between changes because mirtazapine's elimination half-life is 20–40 hours, and steady-state plasma levels require approximately 5 days. 1

Evidence for Appetite Stimulation and Weight Gain

• In older adults with dementia, depression, and weight loss, mirtazapine 30 mg daily produced mean weight gains of 1.9 kg at 3 months and 2.1 kg at 6 months, with approximately 80% of patients experiencing weight gain. 2, 3
• In patients with advanced non-small cell lung cancer and anorexia, mirtazapine 15 mg titrated to 30 mg significantly increased total energy intake by 379 kcal/day at 4 weeks and increased fat intake by 14.5 g/day at 8 weeks compared to placebo. 4
• Mirtazapine's appetite-stimulating effect is mediated primarily by potent histamine H₁-receptor antagonism in the hypothalamus, which directly increases appetite and food intake. 1

Dose-Specific Considerations for a 72-Year-Old

• Elderly patients exhibit 40% lower oral clearance (in men) and 10% lower clearance (in women) compared to younger adults, resulting in higher plasma mirtazapine levels and longer elimination half-lives (mean 37 hours in elderly women vs. 26 hours in younger males). 1
• Because of reduced clearance in older adults, the 15 mg starting dose is particularly important to minimize sedation, orthostatic hypotension, and falls. 1
• The 30 mg daily dose is the most extensively studied regimen for appetite stimulation in geriatric populations and balances efficacy with tolerability. 2, 5, 3

Clinical Algorithm for Dosing

Week 0–2:

• Prescribe mirtazapine 15 mg once daily at bedtime. 1
• Monitor for sedation, dizziness, orthostatic hypotension, and nightmares (reported in some patients during the first 2 weeks). 4
• Assess appetite, food intake, and body weight at baseline and week 2. 3

Week 2–4:

• If the patient tolerates 15 mg and appetite remains inadequate, increase to 30 mg once daily at bedtime. 1
• Continue monitoring weight, appetite, and adverse effects weekly. 3

Week 4–12:

• Maintain 30 mg daily if appetite and weight are improving. 2, 3
• Measure body weight monthly; clinically meaningful weight gain is typically 2–4% of baseline weight by 3 months. 3
• If weight gain plateaus or remains insufficient after 8 weeks at 30 mg, consider increasing to 45 mg daily, though evidence for this higher dose in appetite stimulation is limited. 1

Beyond 12 weeks:

• Reassess the need for continued mirtazapine therapy every 3 months. 1
• If the patient has achieved adequate weight restoration and appetite is stable, consider gradual dose reduction over several weeks rather than abrupt discontinuation to avoid withdrawal symptoms. 1

Critical Contraindications and Cautions

• Do NOT prescribe mirtazapine solely for appetite stimulation in patients with dementia who do not have concurrent depression; guideline consensus states that appetite stimulants should not be used in dementia without depression because evidence is weak and adverse effects are notable. 2
• Mirtazapine may be appropriate when a 72-year-old patient has both depression and weight loss, as it addresses both conditions simultaneously. 2, 5
• Common adverse effects include sedation (due to H₁ antagonism), orthostatic hypotension (due to α₁-adrenergic antagonism), and constipation (due to moderate anticholinergic activity); these risks are heightened in older adults. 1
• Nightmares were reported more frequently in the first 2 weeks of mirtazapine therapy in one controlled trial, but this effect typically resolves with continued treatment. 4
• Avoid combining mirtazapine with monoamine oxidase inhibitors (MAOIs); allow at least 14 days between discontinuing an MAOI and starting mirtazapine, and vice versa. 1

Monitoring Protocol

Parameter	Frequency	Rationale
Body weight	Weekly for 4 weeks, then monthly	Detect clinically meaningful weight gain (≥2 kg or ≥3% of baseline) [3]
Appetite assessment	Every 2 weeks for 8 weeks	Subjective improvement typically precedes measurable weight gain [4]
Blood pressure (sitting and standing)	At each visit	Screen for orthostatic hypotension, especially in the first 2 weeks [1]
Sedation and falls risk	Weekly for 4 weeks	Sedation is most pronounced early in treatment and may increase fall risk [1]
Mood and depressive symptoms	Every 4 weeks	If depression is present, assess response to antidepressant effect [1]

Common Pitfalls and How to Avoid Them

• Pitfall: Starting at 30 mg in an elderly patient.
  Solution: Always initiate at 15 mg to assess tolerability, then titrate to 30 mg after 1–2 weeks. 1

• Pitfall: Prescribing mirtazapine for appetite stimulation in a patient with dementia but no depression.
  Solution: Guideline consensus recommends against this practice; use mirtazapine only when depression coexists with weight loss. 2

• Pitfall: Expecting immediate weight gain.
  Solution: Weight gain typically becomes evident after 3–4 weeks of therapy; appetite improvement may occur earlier. 4, 3

• Pitfall: Abrupt discontinuation after weight restoration.
  Solution: Taper mirtazapine gradually over several weeks to avoid withdrawal symptoms such as nausea, anxiety, and insomnia. 1

• Pitfall: Overlooking drug interactions in polypharmacy.
  Solution: Review concomitant medications; mirtazapine is metabolized by CYP2D6, CYP1A2, and CYP3A4, so inhibitors or inducers of these enzymes may alter plasma levels. 1

Alternative Appetite Stimulants (Not Recommended in This Context)

• Megestrol acetate and corticosteroids are used in cancer-related cachexia but carry significant risks (thromboembolic events, adrenal suppression, muscle loss) and are not appropriate for routine appetite stimulation in older adults without cancer. 6, 7
• Cannabinoids have not demonstrated consistent efficacy for appetite stimulation in controlled trials and are not recommended. 2
• Dronabinol has not shown appetite-stimulating effects in rigorous clinical trials. 7